Introductory Overview
CVS Health, a leading U.S. health‑care provider and pharmacy‑retail chain, has demonstrated robust growth and solid market positioning. Over the past year the stock has gained 57.06 %, reflecting the company’s expanding services and steady revenue stream. The latest closing price is US $104.72, with a 52‑week high of US $106.15 and a low of US $58.5. Market cap stands at US $133.62 billion and the price‑earnings ratio is 45.35. Analysts are watching CVS closely as a large‑cap player in health‑care services.
5‑Year Investment Gain
A recent calculation from finanzen.net shows that a $100 investment in CVS five years ago (price $82.43) would be worth $127.04 today, a 27.04 % return. This reflects a cumulative rise in share price from $82.43 to $104.72, excluding any stock splits or dividend payments. The performance aligns with the broader trend of health‑care stocks benefiting from increased demand for pharmacy and benefits management services.
Analyst Attention and Sector Momentum
Benzinga highlighted that CVS, along with UnitedHealth Group (UNH) and Humana, are attracting significant analyst coverage. The company’s diversified portfolio—including prescription drugs, retail pharmacy, pharmacy‑benefits management (PBM), and disease‑management programs—provides multiple revenue channels. Wall Street analysts note that CVS’s strong cash position and strategic acquisitions position it to capitalize on evolving payer‑provider dynamics.
BlackRock’s Growing Stake
Investing.com reports that BlackRock has increased its ownership in CVS to a 5 % stake. The move signals confidence from one of the largest asset‑management firms in the world. BlackRock’s investment could bring additional scrutiny on ESG practices and operational efficiency, potentially influencing the company’s strategic decisions.
CVS HEALTH CORP Financial Overview
| Category | Value |
|---|---|
| Symbol | CVS |
| ISIN | US1266501006 |
| Last Close (07/01/2026) | $104.72 |
| Market Cap | $133,620,000,000.00 |
| P/E Ratio | 45.35 |
| Price/Sales Ratio | 0.33 |
| Price/Book Ratio | 1.72 |
| 52W High / Low | 106.15 / 58.50 USD |
| Daily Change | 0.01% |
| Weekly Change | 0.37% |
| Monthly Change | 14.62% |
| Yearly Change | 57.06% |
| Shares Outstanding | 1,275,973,998 |
| Dividend | $2.54 |
| Exchange | New York Stock Exchange (America/New_York) |
Key Takeaway
CVS Health has delivered solid performance over the past year and continues to attract analyst and institutional interest. While the stock shows strong upside potential relative to its 5‑year history, investors should monitor earnings releases, PBM contract renewals, and the impact of BlackRock’s stake on corporate governance.
Conclusion
If you are evaluating a position in CVS Health, consider the company’s proven track record, diverse service mix, and growing institutional support. The current data provides a clear, factual basis for assessing the stock’s recent performance, without recommending a specific trade action.
